Cargando…
Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609079/ https://www.ncbi.nlm.nih.gov/pubmed/34480292 http://dx.doi.org/10.1007/s13311-021-01102-w |
| _version_ | 1784602855494123520 |
|---|---|
| author | Hartung, Hans-Peter Mares, Jan Meuth, Sven G. Berger, Thomas |
| author_facet | Hartung, Hans-Peter Mares, Jan Meuth, Sven G. Berger, Thomas |
| author_sort | Hartung, Hans-Peter |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8609079 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86090792021-12-03 Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk Hartung, Hans-Peter Mares, Jan Meuth, Sven G. Berger, Thomas Neurotherapeutics Commentary Springer International Publishing 2021-09-03 2021-07 /pmc/articles/PMC8609079/ /pubmed/34480292 http://dx.doi.org/10.1007/s13311-021-01102-w Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Commentary Hartung, Hans-Peter Mares, Jan Meuth, Sven G. Berger, Thomas Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk |
| title | Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk |
| title_full | Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk |
| title_fullStr | Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk |
| title_full_unstemmed | Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk |
| title_short | Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk |
| title_sort | multiple sclerosis: switching from natalizumab to other high-efficacy treatments to mitigate progressive multifocal leukoencephalopathy risk |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609079/ https://www.ncbi.nlm.nih.gov/pubmed/34480292 http://dx.doi.org/10.1007/s13311-021-01102-w |
| work_keys_str_mv | AT hartunghanspeter multiplesclerosisswitchingfromnatalizumabtootherhighefficacytreatmentstomitigateprogressivemultifocalleukoencephalopathyrisk AT maresjan multiplesclerosisswitchingfromnatalizumabtootherhighefficacytreatmentstomitigateprogressivemultifocalleukoencephalopathyrisk AT meuthsveng multiplesclerosisswitchingfromnatalizumabtootherhighefficacytreatmentstomitigateprogressivemultifocalleukoencephalopathyrisk AT bergerthomas multiplesclerosisswitchingfromnatalizumabtootherhighefficacytreatmentstomitigateprogressivemultifocalleukoencephalopathyrisk |